|
Volumn 12, Issue 9, 2017, Pages e143-e144
|
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ALKALINE PHOSPHATASE;
ASPARTATE AMINOTRANSFERASE;
CISPLATIN;
CYTOKERATIN 19;
NIVOLUMAB;
PEMETREXED;
IMMUNOLOGICAL ANTINEOPLASTIC AGENT;
ABSCOPAL EFFECT;
ADJUVANT CHEMORADIOTHERAPY;
ADULT;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ALKALINE PHOSPHATASE BLOOD LEVEL;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
BILIRUBIN BLOOD LEVEL;
CANCER GRADING;
CANCER STAGING;
CASE REPORT;
CLINICAL ARTICLE;
FOLLOW UP;
HUMAN;
JAPANESE (PEOPLE);
LETTER;
LIVER METASTASIS;
LOBECTOMY;
LUNG ADENOCARCINOMA;
LUNG METASTASIS;
LYMPH NODE DISSECTION;
MALE;
MEDIASTINUM LYMPH NODE;
MIDDLE AGED;
MULTIPLE CYCLE TREATMENT;
ONCOLOGICAL PARAMETERS;
PRIORITY JOURNAL;
RADIATION DOSE DISTRIBUTION;
RADIATION DOSE FRACTIONATION;
TUMOR VOLUME;
X-RAY COMPUTED TOMOGRAPHY;
LUNG TUMOR;
PATHOLOGY;
ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;
HUMANS;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
NIVOLUMAB;
|
EID: 85028303458
PISSN: 15560864
EISSN: 15561380
Source Type: Journal
DOI: 10.1016/j.jtho.2017.05.004 Document Type: Letter |
Times cited : (21)
|
References (4)
|